United States Patent

Belardinelli et al.

[54] A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS


[12] Notice: The term of this patent shall not extend beyond the expiration date of Pat. No. 5,631,260.

[21] Appl. No.: 470,113

[22] Filed: Jun. 6, 1995

Related U.S. Application Data


[51] Int. Cl. A61K 31/52; C07D 473/08; C07D 473/06; C07D 473/34

[52] U.S. Cl. 514/263; 536/27; 526; 544/267; 544/276; 544/277

[58] Field of Search 514/263

References Cited

U.S. PATENT DOCUMENTS

4,364,922 12/1982 Berne et al. 424/9
4,713,455 12/1987 Furrer et al. 544/267
4,980,379 12/1990 Belardinelli et al. 514/821
5,288,721 2/1994 Klein et al. 514/263

FOREIGN PATENT DOCUMENTS

4205306 8/1993 Germany
9200297 1/1992 WIPO
9416702 8/1994 WIPO

OTHER PUBLICATIONS


Primary Examiner—Mark L. Berch
Attorney, Agent, or Firm—Saliwanchik, Lloyd & Saliwanchik

ABSTRACT

Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.

7 Claims, 9 Drawing Sheets

[57]
**A1 Response**

**S-H Prolongation (msec)**

- Ado
- Ado + ENX
- Ado

**Fig. 4C**

**A2 Response**

**Δ Coronary conductance (ml/min/mmHg)**

- Ado
- Ado + ENX
- Ado

**Fig. 4D**
FIG. 5A

CONTROL

\( \frac{dP}{dt}_{\text{max}} = 1399 \pm 15 \text{ mmHg/sec} \)

FIG. 5B

ENX 2 \( \mu \text{M} \)

\( \frac{dP}{dt}_{\text{max}} = 1445 \pm 29 \text{ mmHg/sec} \)

FIG. 5C

ENX 200 \( \mu \text{M} \)

\( \frac{dP}{dt}_{\text{max}} = 1377 \pm 8 \text{ mmHg/sec} \)

FIG. 5D

WASHOUT

\( \frac{dP}{dt}_{\text{max}} = 1451 \pm 16 \text{ mmHg/sec} \)
$^{3}\text{H}$-Adenosine Formed, % Control

FIG. 6
FIG. 7
FIG. 8

- **Vehicle (control)**
- **ENX (S-enantiomer)**
- **ENX (R-enantiomer)**
- **ENX (racemic mixture)**

**Accumulative Urine Output (ml)**

- Hours: 1, 2
A1 ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS

CROSS REFERENCE TO A RELATED APPLICATION

This is a continuation of application Ser. No. 08/330,640, filed Oct. 28, 1994 U.S. Pat. No. 5,631,260 which is a continuation-in-part of application Ser. No. 08/144,459, filed Oct. 28, 1993 U.S. Pat. No. 5,446,046.

BACKGROUND OF THE INVENTION

Adenosine is an extracellular messenger generated by all cells in the body. Adenosine itself, substances that mimic the actions of adenosine, and substances that antagonize its actions have important clinical applications. In the heart, an organ whose function depends critically on an adequate supply of oxygen, adenosine regulates the balance between oxygen supply (coronary blood flow) and oxygen demand (cardiac work). Adenosine released from working heart cells increases oxygen supply through coronary dilation and decreases oxygen consumption by slowing heart rate and modulating β-adrenergic stimulation. The protective effects of adenosine are particularly important when cardiac oxygen supply is limited, for example, by coronary artery narrowing.

Several recent reviews describe the adenosine system in detail (Belardinelli, L., J. Linden, R. M. Berne [1989] Prog. Cardiovasc. Dis. 32:73–97; Belardinelli, L., A. Pellegrini [1990] J. Cardiovasc. Electrophysiol. 1:327–339; Olsson, R. A., J. D. Pearson [1990] Physiol. Rev. 70:761–845). The cardiac adenosine system consists of three processes: (1) mechanisms for adenosine formation; (2) adenosine receptor and proteins that couple them to effectors; and (3) mechanisms for the removal of adenosine. Selective modifications of these systems by means of drugs such as adenosine receptor antagonists and adenosine uptake inhibitors can modify the actions of adenosine for therapeutic benefit.

Adenosine formation increases when oxygen demand exceeds its supply, thereby promoting the degradation of adenosine nucleotides. The degradation of adenosylates released from nerve terminals along with neurotransmitters and the degradation of S-adenosylhomocysteine, a byproduct of methylation reactions, are additional sources of adenosine in the heart. Heart muscle and coronary blood vessel cells take up very nearly all the adenosine generated in the heart, reincorporating that adenosine into the cellular nucleotide pool.

At least two types of receptors mediate the actions of adenosine in the heart. A1 adenosine receptors (A1AR) increase oxygen consumption, for example, by slowing heart rate, and A2 adenosine receptors (A2AR) increase oxygen supply by causing coronary vasodilation. The actions of adenosine on cardiac cells are either direct (cAMP-independent) or indirect (cAMP-dependent). The direct actions include the negative inotropic effect on the AV node. Those electrophysiological effects are the basis of adenosine’s anti-arrhythmic properties; adenosine is highly effective (>90%) in terminating paroxysmal supraventricular tachycardia (PSVT). The A2AR-mediated inhibition of agonist-stimulated (but not basal) adenylate cyclase activity constitutes the indirect effects of adenosine. Whereas the direct effects of adenosine occur in the absence of agents that act through adenylate cyclase, the indirect effects reflect the inhibition of this enzyme when it is stimulated by agents such as β-adrenergic agonists.

A number of pharmacological studies employing receptor-selective agonists support the idea that A1ARs mediate coronary vasodilation. Although endothelial cells contain A2ARs and thus could play a role in vasodilation, they are not essential, for adenosine acts on coronary smooth muscle cells, causing them to relax.

When adenosine is used as a drug, its side effects are usually transitory, a reflection of its extremely rapid degradation in the body (seconds). The safety of adenosine in the diagnosis and treatment of PSVT is now well established. An important factor which has inhibited the therapeutic development of the adenosine analogues is the ubiquitous nature of adenosine’s action on a variety of tissues.

Two kinds of drugs modify the actions of adenosine according to whether they magnify or attenuate the effects of the nucleoside. Inhibitors of the cell membrane nucleoside transporter block the removal of adenosine from the extracellular space, thereby increasing its concentration and intensifying its action. Adenosine uptake blockers also inhibit the nucleoside transport system in human erythrocytes and cardiocyte membranes and potentiate the cardiac actions of adenosine in the dog.

Methylxanthines competitively antagonize the binding of adenosine to both the A1AR and the A2AR. Certain naturally occurring methylxanthines such as caffeine and theophylline antagonize the cardiovascular effects of adenosine. For example, the administration of adenosine to patients receiving theophylline fails to produce AV block or terminate PSVT. However, those methylxanthines are relatively weak and, more importantly, are nonspecific, antagonizing both the electrophysiological and vasodilatory effects of adenosine in laboratory animals and humans. Theophylline also ameliorates the non-cardiac effects of adenosine such as flushing, local pain, and respiratory stimulation.

Synthetic alkylxanthines, e.g., 8-cyclopentyl-1,3-dipropylxanthine (CPX; see U.S. Pat. Nos. 4,364,922 and 4,980,379), are significantly more potent and selective antagonists at the A1AR than are theophylline or caffeine.

BRIEF SUMMARY OF THE INVENTION

The present invention concerns the discovery of certain novel compounds which can bind to adenosine receptors with surprisingly high affinity, specificity, and selectivity. Specifically exemplified herein are xanthine and adenosine analogues comprising an epoxide moiety. As explained in more detail herein, these adenosine agonists and antagonists have therapeutic utility in a broad range of applications including cardiac and renal regulation. Included among these novel compounds are both adenosine agonists and antagonists.

In one embodiment of the subject invention, the novel compound known as 1,3-dipropyl-8-[3-oxatricyclo[3.1.0.0^2,4](6,7)-yl]xanthine, herein referred to as ENX, is used as an antagonist of adenosine. Advantageously, ENX has been found to be uniquely potent, specific, and highly selective for the A1 adenosine receptor. Particular enantiomers of the ENX compound were synthesized and tested for their relative activity. Testing of R-and S-enantiomers of ENX revealed advantages of the S-enantiomers, namely, potency and selectivity for the A1AR greater than those of the racemate or the R-enantiomer. However, the R-enantiomer, by virtue of its shorter biological half-life, can be advantageous in defined therapeutic applications requiring a short duration of action.

The subject invention further concerns other xanthines and adenosines comprising an epoxide moiety in an exocy-
clic substituent. Further embodiments of the invention include compositions and formulations comprising ENX or those analogues or derivatives which can have therapeutic utility as agonists or antagonists of adenosine.

A further aspect of the subject invention is a method for using the disclosed compounds for modulating the biological activity of adenosine. The compounds, or compositions comprising these compounds, can be utilized for their modulating effect on adenosine, e.g., as agonists or antagonists of adenosine receptors. The antagonist activity of the subject compounds can be utilized in treating conditions where elevated levels of adenosine are present; the agonist can be useful where stimulation of the adenosine receptor is needed. Such conditions include, but are not limited to, cardiac, renal, hepatic, or lung diseases, such as cardiac arrhythmias, renal failure, liver failure ascites, and asthma. Modulating adenosine activity can also be used in the treatment of maturity onset diabetes.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a scheme outlining the syntheses of 1,3-dipropylxanthines having C-8 substituents that contain an epoxide moiety.

FIG. 2 is a scheme for the synthesis of adenosine derivatives containing an epoxide moiety.

FIG. 3 shows synthesis of (2R)- and (2S)- and (2S)-endo-5-norborn-2-carboxylic acids.

FIGS. 4A-4D show selective antagonism of the negative dromotropic (S-H interval prolongation) effect of adenosine (Ado) by ENX. FIGS. 4A-4B show an analog record of the prolongation of the S-H interval (A1 response, FIG. 4A) and the increase in coronary conductance (A2 response, FIG. 4B) caused by a 3 minute infusion of adenosine (4 µM) in the absence and presence of 0.4 µM ENX. ENX inhibited the negative dromotropic effect of adenosine, but did not antagonize the coronary vasodilation (increase in coronary conductance) caused by adenosine. FIGS. 4C-4D show selective antagonism by ENX (0.4 µM) of the A1 receptor mediated increase in the S-H interval caused by adenosine (4 µM), but not the A2 receptor mediated coronary vasodilation. The values are the mean ±SEM from five guinea pig hearts. The asterisk is indicated by those values significantly different from adenosine alone (P<0.05).

FIGS. 5A-5D show a lack of effect of ENX on left ventricular pressure (LVP) and dp/dt max. Guineapig hearts were atrial paced at a constant cycle length of 300 msec and exposed to progressively higher concentrations of ENX, i.e., 2 and 200 µM. In the same hearts ENX alone caused no significant changes in the stimulus-to-His bundle interval (not shown). Identical results were obtained in three other hearts.

FIG. 6 shows the effect of ENX and isobutylmethylxanthines (IBMX) on phosphodiesterase (PDE) activity in homogenates of DDT,MF-2 cells. The data for IBMX, shown as squares in the figure, clearly shows inhibition of phosphodiesterase activity. In contrast, phosphodiesterase activity following ENX administration, shown as circles in the figure, remained constant and showed no inhibition.

FIG. 7 shows the specificity of action of ENX to antagonize the negative dromotropic effect (S-H prolongation) of adenosine in guinea pig heart. The effect of ENX (2 nM, 2 µM) on similar S-H prolongation caused by adenosine (ADO, 4 µM), magnesium (Mg2+, 3 mM), and carbachol (CCH, 0.14 µM) was determined. The height of each bar graph presents the mean ±SEM of 4 experiments. Only the S-H interval prolongation caused by adenosine was antagonized by ENX.

FIG. 8 shows accumulative urine output in rats intravenously given 0.1 mg/kg of ENX (racemic mixture); ENX (R-enantiomer); ENX (S-enantiomer); and a vehicle used as a control.

DETAILED DESCRIPTION OF THE DISCLOSURE

The subject invention pertains to novel compounds, and formulations comprising those compounds, which can advantageously be used as either agonists or antagonists at adenosine receptors. Specifically, these compounds either promote or antagonize the negative dromotropic, chronotropic, and isotropic effects mediated by an A1 adenosine receptor (A1,AR). In the heart, these compounds can either promote or antagonize the negative dromotropic, chronotropic, and isotropic effects mediated by A1,AR, and in the kidney the antagonists promote diuresis through an A1,AR.

The subject compounds are of two general types: (1) 3-dialkylxanthines having C-8 substituents that comprise an epoxide (oxiranyl) moiety, and (2) adenosines having N-6 substituents that comprise an epoxide moiety. In a preferred embodiment of the subject invention, the xanthine epoxides are 1,3-dialkylxanthines having an epoxide moiety covalently bound to the C-8 substituent of xanthine. The preferred epoxides of xanthine or adenosine are those having an epoxide moiety as part of an exocyclic substituent.

The general structure of one class of 1,3-dialkylnxanthines is shown below as Formula I:

\[
\text{O} \quad \text{H} \quad \text{N} \quad \text{R}_1 \quad \text{R}_2
\]

wherein R1 and R2 are the same or different, and can be an alkyl group of 1-4 carbons in length; and n=0-4. It would also be understood that R1 and/or R2 can be a hydrogen.

Compounds which have one of the R-groups as hydrogen and the other R-group as an alkyl would be epoxides of alkyl xanthine; compounds having both R-groups as alkyls are epoxides of dialkylxanthine.

The general structure of the 1,3-dialkyl-8-oxatricycloalkylxanthines is shown below as Formula II:

\[
\text{O} \quad \text{H} \quad \text{N} \quad \text{R}_1 \quad \text{R}_2
\]

wherein R1 and R2 are the same or different, and can be a hydrogen or an alkyl group of 1-4 carbons; R3 is either O or an alkyl group of 1-4 carbons; and n=0-4.

A polymethylene chain 1-4 carbons in length can link the epoxide moiety to C-8 of 1,3-dialkylxanthine, as in Formula I. The epoxide group can also be part of an exocyclic substituent linked to C-8 of the xanthine moiety, either directly or through a (polymethylene chain 1-4 carbons long, as in Formula II. The exocyclic substituent, shown as Formula II, can be a bicycloalkyl group, forming an oxatricycloalkyl substituent. Other exocyclic epoxide structures can also be part of the compound as would be readily...
recognized by those skilled in the art having the benefit of this disclosure. The bicycloalkyl group can further contain an alkenyl group for the formation of a second epoxide moiety.

FIG. 1 depicts a general synthesis scheme for the 8-substituted 1,3-dipropylxanthines.

A preferred embodiment of the subject invention is a compound having the chemical name 1,3-dipropyl-8-[3-oxatricycloc[3.1.0.0^2]oct-6(7)-yl]-xanthine, which is commonly termed epoxy norbornylxanthine, or ENX. The formula for ENX is shown as Formula III, below:

\[
\begin{align*}
\text{CH}_3\text{C}_6\text{H}_5\text{N} & \quad \text{O} \\
\text{N} & \quad \text{CH}_3\text{C}_6\text{H}_5\text{N} \\
\text{O} & \quad 
\end{align*}
\]

ENX has been demonstrated to have advantageous and unexpected properties as an adenosine antagonist by its high selectivity and affinity for the \(A_1\) adenosine receptor.

Essentially, a patient who has any condition where levels of endogenous adenosine are, or could become, excessive can benefit from therapeutic use of the subject antagonist compound or a composition comprising the compound. For example, the subject invention pertains to the use of the subject antagonist compounds as diuretics or in the treatment of renal failure. In addition, the subject antagonist compounds or compositions comprising these compounds can be employed in the treatment of certain conditions affecting the heart, including bradyarrhythmias associated with hypoxia or ischemia (myocardial infarction), sick sinus node syndrome, and in heart failure, where the positive inotropic effect of the antagonist can be advantageous. Other conditions which are recognized as resulting from, or affected by, elevated levels of endogenous adenosine can also be treated with the subject adenosine antagonists.

The high selectivity and affinity for \(A_1\) adenosine receptor exhibited by the subject compounds, e.g., ENX, make them particularly useful as diuretics. The potency of ENX as a diuretic has been demonstrated to be at least as high as the potency of furosemide (Lasix), a commonly used diuretic in human and animal medicine. Thus, it would be understood that ENX could be used in a manner comparable to the way furosemide is used to produce a diuretic effect in a patient.

The diuretic activity exhibited by ENX can be exploited in the treatment of several conditions commonly affecting mammals, especially humans. For example, congestive heart failure (CHF) is a condition in which diuretics are extensively used. Hypertension, often a concurrent condition with CHF, is also regularly treated with diuretics. ENX was shown to have comparable diuretic activity and potency as currently marketed diuretics, e.g., Lasix, used for treatment of such conditions. Thus, the subject compounds, especially ENX, can be used in a similar manner for treatment of these conditions.

The subject adenosine antagonists can also be indicated as nephroprotecting compounds. ENX, which has been shown to bind to the \(A_1\) adenosine receptor, can be used to block those receptors during the use of contrast agents known to be nephrotoxic, or can be useful in treatments to counteract the nephrotoxic effects of certain antibiotics, e.g., gentamycin, amphotericin, or cyclosporin.

In addition, the subject \(A_1\) adenosine antagonists, e.g., ENX, can be useful for treatment of the ascites of liver failure. As would be readily understood in the art, ENX can be useful with certain modifications of treatment regimens and indications for non-transplant patients suffering from liver failure, pre-transplant patients, or for transplant patients having hepatorenal syndrome.

The activity as an adenosine \(A_1\) receptor inhibitor and diuretic indicates that the subject antagonist compounds, e.g., ENX, also can be used as an analgesic, especially in the treatment of angina, claudication, and bradyarrhythmias associated with ischemia, hypoxia, or repertussion. Also, the use of exogenously administered adenosine in cardiac diagnostic procedures, e.g., imaging of cardiac vasculature, is known to produce transitory side effects, including a brief onset of pain. As this side effect has been attributed to adenosine’s binding to, and stimulation of, the \(A_2\) receptor (but not the \(A_1\) receptor), an adenosine antagonist inhibiting the binding of adenosine to that \(A_2\) receptor can be used to counteract the pain experienced by a patient undergoing the procedure. The subject compounds, including ENX, selectively bind to the \(A_1\) adenosine receptor, inhibiting the binding of adenosine (and thus blocking or counteracting any side effect associated with the binding of adenosine to the \(A_1\) receptor).

Further, the subject antagonist compounds, including ENX, can be used as a bronchodilator, i.e., an antiasthmatic. ENX has been shown to relax tracheal smooth muscle, thus producing bronchodilation. This property is also common to other much weaker xanthine derivatives, e.g., theophylline. Such use of the subject antagonist compounds as an antiasthmatic treatment suggests that the compound can be useful when administered via an inhalation route.

Other routes of administration of the subject compounds can also be used. For example, it is generally contemplated to administer the compounds according to the optimal route indicated for the condition being treated. Thus, the compounds can be administered intravenously, per os, transdermally, etc., and in single or multiple dosage regimens, as would be understood by a person of ordinary skill in the art.

It would also be understood by ordinarily skilled artisans that the above-described uses for the subject compounds can be optimized by using particular isomers which demonstrate different biological activities. Having a chiral center, ENX is recognized to exist in at least two enantiomeric forms. The ENX enantiomers, namely, the S-enantiomer and the R-enantiomer, have been synthesized as the R- and S-isomers of 5-norbornene-2-carboxylic acid by methods available in the art. See Poll, T. et al. (1985) Tetrahedron Lett. 26:3995-3998, and Poll, T. et al. (1989) Tetrahedron Lett. 30:5595-5598. The endo-R- and endo-S-enantiomers of ENX are shown as Formulas IV and V, respectively.
Studies conducted on the two enantiomers of ENX show that both are selective for the A1 AR as compared to the A2 AR. The S-enantiomer has a longer duration of action than the R-enantiomer. Although a racemic mixture of the R- and S-enantiomers can have the biological activity of either or both isomers, it is now understood that the S- and R-isomers can be used separately, as a single enantiomer, to effect particular advantageous activities of either enantiomer.

For example, about 80-90% of the biological activity demonstrated by a racemic mixture of ENX is accounted for by the S-enantiomer. This result is primarily due to the very short duration of activity by the R-enantiomer as compared to the duration of action exhibited by the S-enantiomer. The prolonged action of the S-enantiomer can be due to a slower clearance rate in the liver, e.g., slower metabolic degradation by enzyme systems such as cytochrome P450. The S-enantiomer, which showed slightly increased potency in vitro as compared to the R-enantiomer, showed substantially higher potency in vivo, and consequently higher selectivity for the A1 adenosine receptor as compared to the A2 receptor. See Example 4 for specific data comparing the selectivity and affinity properties of the S- and R-enantiomers of ENX.

The advantageous properties, e.g., increased potency (in vitro and in vivo) and higher selectivity, as well as the longer duration of action exhibited by the S-enantiomer, indicates that the S-enantiomer can be very useful as a diuretic in animals and humans. In most instances, as those exemplified above, the S-enantiomer can be the preferred compound because the length of its duration of activity, which is more than that of the R-enantiomer, can be critical to achieving its effect. In other words, the compound must at least cause an effect long enough to accomplish the desired result.

On the other hand, in instances where short duration of action are desired, e.g., during intravenous infusion of adenosine or onset of myocardial ischemia, when the onset of increased adenosine levels is rapid and lasts only for a short period of time (on the order of seconds or minutes), an adenosine antagonist having a short duration of action, e.g., the R-enantiomer of ENX, can be advantageously used. The activity of the ENX R-enantiomer is beneficial for short periods of time. However, the R-enantiomer of ENX is rapidly degraded or metabolized. This rapid metabolism can prevent complications associated with drug interactions became the concentrations of the ENX R-enantiomer are rapidly decreased. Due to its analgesic properties, the R-enantiomer of ENX can be administered for the acute pain of angina.

Another application of the subject compounds having a short duration of action is as an antiasthmatic or bronchodilator. It has been suggested that the high biological activity shown for the S-enantiomer of ENX is due to the rapid and selective metabolism of the R-enantiomer of ENX in the liver. This can be due to a first-pass effect exhibited for the R-enantiomer when administered by routes in which the drug is degraded by liver enzymes prior to or at about the same time as it reaches the appropriate receptors where the pharmacologic effect is induced. However, certain other routes of administration can be advantageously used to exploit this first-pass effect. For example, the S- and R-enantiomers of ENX have been demonstrated to be bronchodilators. Administration of the R-enantiomer alone (or in a composition comprising the R-enantiomer but not the S-enantiomer) by inhalation immediately presents the compound to the appropriate receptors in the trachea and bronchi to cause its action. Any absorbed compound is rapidly eliminated, which reduces residual levels of the compound in the body.

Derivatives of adenosine containing an epoxide moiety, particularly those having an epoxide moiety in an N-6 substituent, can be used as A1 AR agonists. Epoxide derivatives of adenosine agonists can also display high selectivity for adenosine receptors. High selectivity for cardiovascular tissue is also demonstrated. More specifically, N6-substitution of adenosine with epoxycycloalkyl groups can result in potent and tissue-selective agonists.

The N6-subregion of the A1 adenosine receptor contains chiral recognition sites which can be important for the determination of A1/A2 selectivity. The epoxide can be substituted as a cycloalkyl substituent, e.g., cyclopentyl, norbornanyl, or adamantyl derivative of adenosine. Shown below as Formula VI is an adenosine epoxide having the epoxide substituent at the N6 position. The epoxide can be attached as a cyclopentyl or norbornanyl group.

![Chemical Structure](image)

(VI)
5,668,139


The subject adenosine agonists can be useful for the treatment of a patient where stimulation of A<sub>1</sub>AR is needed. Uses for the subject adenosine agonists and compositions comprising those agonists include their use as a functional β-blocker; as an antiarrhythmic agent for the control of heart rate, including supraventricular tachyarrhythmias, cardiac arrhythmias; diabetes type II; and cardioprotection, e.g., decrease infarct size and increase tolerance to myocardial ischemia.

The compounds of the subject invention (agonists and antagonists) can be formulated with a pharmaceutically acceptable carrier into a composition that can be administered to a patient who would benefit from the adenosine receptor agonist or antagonist properties of the subject compounds or compositions. Advantageously, dosages of the subject adenosine antagonists for treating post-resuscitation cardiac arrhythmias can be less than the 0.1-20 mg/kg range which has been previously reported for known adenosine antagonists. See U.S. Pat. No. 4,980,379. An effective dose can be recognized as the dose at which the alleviation of bradycardia and reversal of hemodynamic collapse occurs.

Standard procedures for administration of adenosine antagonists such as theophylline and aminophylline at effective dosage levels are well established and are well known to those skilled in the art. For example, the recommended therapeutic range for plasma levels of theophylline for patients with reversible obstruction of the airways is from 10-20 μg/ml. The subject compounds, having high selectivity and potency, can be useful and effective at known concentrations in the blood.

The above list of treatment uses for the subject compounds or compositions is by no means exhaustive, and other situations where the subject invention could be advantageously employed would be readily recognized by ordinarily skilled persons in this art. For example, it would be readily recognized in the art that other conditions which can be treated by reducing the effects of elevated endogenous adenosine or by increasing stimulation of the A<sub>1</sub>AR can also benefit from the use or administration of the subject adenosine antagonists or agonists, respectively.

Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

**EXAMPLE 1**

**Preparation of 8-Epoxyalkylxanthines**

**Chemistry**

The scheme shown in FIG. 1 outlines the syntheses of 1,3-dipropylxanthines having C-8 substituents comprising an epoxide moiety. The reaction of 5,6-diamino-1,3-dipropyluracil, 1, with an α-alkenyl halide or an α-alkenoyl ester gave an amide 2, which was then cyclized in hot alkali to form the 8-α-alkenyl-1,3-dipropylxanthine 3. Oxidation with m-chloroperbenzoic acid yielded the 8-epoxyalkylxanthine 4. Alternatively, the Diels-Alder condensation of 3 with a 1,3-cycloalkadiene generated an 8-bicycloalkylxanthine 5. When furan was the alkadiene the product was the 8-ω-[7-oxabicyclo[2.2.1]hept-2-en-5(6)-yl]xanthine 5, which contains both (α) an epoxide moiety and (β) an alkényl moiety that can serve for the formation of a second epoxide moiety. The oxidation of 5 with 2.4 equivalents of meta-chloroperbenzoic acid gave the 8-epoxybicycloalkylxanthine 6.

1.3-dipropyl-8-[3-oxatricyclo[3.2.1.0<sup>2,7</sup>]oct-6(7)-yl]xanthine

A solution of 8-bicyclo[2.2.1]hept-2-en-5(6)ylxanthine (1.0 g, 3 mmol) and m-chloroperbenzoic acid (0.8 g, 3.6 mmol) in 50 ml CH<sub>2</sub>Cl<sub>2</sub> was stirred for 24 hours at room temperature. A second aliquot of peracetic acid and stirring continued for 24 hours. Evaporation gave a yellow oil that was purified by preparative reverse phase HPLC on C-18 silica eluted with a gradient of 70-80% methanol in water. Yield 0.54 g, 52%, mp 149°-150°C. 1.3-dipropyl-8-[7-oxabicyclo[2.2.1]hept-2-en-5(6)]ylxanthine

A suspension of 1,3-dipropyl-5-vinylxanthine (0.4 g, 1.5 mmol) in 50 ml dry THF containing furan (0.22 ml, 3 mmol) was stirred at room temperature. The addition of 1 drop of TMS triflate effected solution, and HPLC showed the disappearance of starting material. Preparative reverse phase HPLC on C-18 silica eluted with a gradient of 50-80% methanol in water yielded 0.25 g (50%) of product.

**EXAMPLE 2**

**Preparation of an Adenosine Derivative Comprising an Epoxide Moiety**

A compound useful as an adenosine agonist is an adenosine derivative comprising an oxabicyclo- or oxatricycloalkyl group as an N-6 substituent. A general scheme for the preparation of the compound is shown in FIG. 2.

N<sub>2</sub>-endo-[3-oxatricyclo[3.2.1.0<sup>2,7</sup>]oct-6(7)-yl]adenosine

A solution of N<sub>2</sub>-(endo-2-norbornene-5-yl)adenosine (0.5 g, 1.4 mmol) in 100 ml dry methanol was cooled to 0-5°C in an ice bath, a solution of dimethylmethylene in acetonitrile (40 ml, 4 mmol) was added; stirring continued for 8 hours in the ice bath and then overnight at room temperature. Evaporation of solvent and purification by chromatography yielded 0.42 g (81%) of a white solid.

**EXAMPLE 3**

**Use of the Novel Compounds as Adenosine Antagonists**

In order to demonstrate the effectiveness of the subject compounds as adenosine antagonists, the activity of the compounds was compared to known antagonists. In addition, the specificity, selectivity, and potency of ENX as an A<sub>1</sub> adenosine receptor antagonist, functional and biochemical (radioligand binding assays) experiments were carried out on guinea pig isolated hearts, in membranes from guinea pig brain, DDT<sub>1</sub>, MF-2, and PC12 cells. The results of these experiments are described below.

1. Functional studies

The functional evidence that an epoxide of alkylxanthine (ENX) specifically and selectively antagonizes cardiac actions of adenosine mediated by A<sub>1</sub>-adenosine receptor but does not antagonize A<sub>2</sub>-adenosine-receptor mediated coronary vasodilation was obtained in the isolated perfused guinea pig heart. The effect of ENX and two other alkylxanthines (NAX and CPX) on the A<sub>1</sub>-receptor mediated changes in stimulus-to-His bundle interval (S-H interval; a measure of AV nodal conduction) and on the A<sub>2</sub> receptor mediated coronary vasodilatation were investigated. The
potency of ENX, NAX, and CPX to antagonize the negative
dromotropic (prolongation of S-H interval) of the A$_1$ agonist
CCPA and vasodilatory effect of adenosine are shown in
Tables 1 and 2.

TABLE 1

| Potency of various alkylxanthines to antagonize A$_1$ receptor-mediated
cardiac response: results of Schild analysis. |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENX</td>
</tr>
<tr>
<td>-----</td>
</tr>
<tr>
<td>PA$_2$</td>
</tr>
<tr>
<td>K$_s$</td>
</tr>
<tr>
<td>(1.2-3.9)</td>
</tr>
<tr>
<td>Slope</td>
</tr>
<tr>
<td>n</td>
</tr>
</tbody>
</table>

Values are mean ± S.E.M. of the PA$_2$ (−log EC$_{50}$), the equilibrium dissociation constant K$_s$, and the slope of Schild plots. Cardiac response: antagonism of the negative dromotropic effect of the selective A$_1$ agonist CCPA. The numbers in parentheses are the minimum and maximum K$_s$ values. n = number of experiments. Neither the PA$_2$ (K$_s$) nor the slope of Schild plots were significantly different among the antagonists.

TABLE 2

| Potency of various alkylxanthines to antagonize A$_1$ receptor-mediated
coronary vasodilatation. |
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENX</td>
</tr>
<tr>
<td>IC$_{50}$</td>
</tr>
<tr>
<td>(0% at 50 µM)</td>
</tr>
<tr>
<td>n</td>
</tr>
</tbody>
</table>

Values are the concentration of antagonist that inhibits 50% (IC$_{50}$) of a maximum coronary vasodilatation caused by adenosine. Values in parentheses are 95% confidence interval of the IC$_{50}$ values. n = number of experiments.

Although all three alkylxanthines were equipotent in antagonizing the A$_1$ receptor-mediated prolongation of the S-H interval, ENX is far more selective than NAX and CPX.

To further demonstrate the selectivity of ENX for A$_1$ vs A$_2$ receptor, measurements of A$_1$/A$_2$ receptor mediated S-H interval and A$_2$-receptor mediated increase in coronary conductance were carried out during administration of adenosine alone and adenosine plus ENX (FIGS. 4A-4D). Adenosine (4 µM), when administered alone, produced a significant increase in S-H interval and coronary conductance. When adenosine was administered together with ENX (0.4 µM), the S-H interval prolongation was completely inhibited, whereas the A$_2$-mediated coronary vasodilatation remained unaltered. After washout of ENX, a third administration of adenosine alone caused a significant prolongation of S-H interval (similar to the first administration of adenosine) and increase in coronary conductance. These findings demonstrate that the effects of ENX are reversible and that ENX antagonizes the A$_2$-receptor mediated S-H prolongation but not the A$_2$-receptor mediated increase in coronary conductance caused by adenosine. These data also demonstrate the capability of ENX to inhibit activity (and thus any side effects) associated with the binding of adenosine to the A$_1$ receptor while the beneficial pharmacological activity of adenosine stimulation of the A$_2$ receptor remains unaffected.

To determine whether ENX had a positive inotropic effect, experiments were conducted to determine its effects on left ventricular pressure (LVP) and its first derivative dP/dt, an index of contractility. As illustrated in FIG. 5, there were no significant changes in either LVP or dP/dt of normoxic guinea pig hearts when these hearts were exposed to increasing concentrations of ENX (2-200 µM). LVP and dP/dt remained constant during the administration of varying concentrations of ENX and washout. These results demonstrate the lack of a positive inotropic effect of ENX.

Consistent with the lack of positive inotropic effect, ENX also did not inhibit the enzyme phosphodiesterase (FIG. 6). Cells were homogenized in 40 mM Tris buffer at pH 8.0, and the whole homogenate was used in the enzyme assays. PDE activity was determined by incubating homogenate (0.4 mg protein) in Tris buffer containing 20 mM MgCl$_2$, 4 mM mercaptoethanol, 0.06 mg bovine serum albumin, 0.4 mM cAMP 130 nCi of $[^{3}H]$cAMP and the indicated concentrations of ENX or IBMX for 45 min at 30°C. Blank incubations were carried out in parallel assays without the homogenate. At the end of the incubation, the suspensions were incubated in a boiling water bath for 2 minutes, transferred to an ice-water bath for 2 minutes and 0.1 mg of snake venom phosphodiesterase was added. The suspensions were incubated for 10 minutes at 30°C, and the adenosine formed was isolated by ion exchange chromatography. The control rate of adenosine formed was 220 pmol/mg protein per minute. The mount of adenosine formed was linear over the incubation period used.

Agents that inhibit the enzyme phosphodiesterase are known to produce positive inotropic effect. The results illustrated in FIG. 6 clearly showed that ENX does not inhibit phosphodiesterase, whereas isobutylmethylxanthine (IBMX, a known positive inotropic agent) inhibits phosphodiesterase. These findings demonstrate an advantage of ENX over other alkylxanthines that are known to inhibit phosphodiesterase and therefore have the potential to produce a positive inotropic action.

Carbachol and MgCl$_2$ were used to test the specificity of antagonism by ENX, e.g., S-H interval prolongation mediated by adenosine As illustrated in FIG. 7. ENX (2 nM, 2 µM) did not antagonize the negative dromotropic effect of carbachol or MgCl$_2$. In contrast, ENX did inhibit the S-H prolongation caused by adenosine.

In summary, the results of the functional experiments described above demonstrate that in the heart, ENX is a reversible, specific, and highly selective antagonist of adenosine at the A$_1$ receptor subtype.

2. Radioligand binding studies

To determine the binding affinities of an epoxide of alkylxanthine, ENX, and compare to other alkylxanthines (CPX, NAX and CPT), radioligand binding experiments were carried out in membranes prepared from brain tissue, DDT, MF-2 and PC12 cell lines. The results of these experiments are illustrated in Tables 3 and 4. The results summarized in Table 3, below, indicate that in brain tissue, ENX is more potent than the other alkylxanthines at the A$_1$AR, whereas in DDT, MF-2 cell the binding affinity of the alkylxanthines for the A$_1$ receptor are approximately the same. With regard to A$_2$ receptors in PC12 cell membranes, ENX was markedly less potent than CPX. In addition, the binding affinity of ENX for the A$_2$, receptor, either brain or DDT, MF-2 cells, was markedly higher than that at the A$_2$, receptor in PC12 cell membranes.
TABLE 3

<table>
<thead>
<tr>
<th>Alkylxanthine</th>
<th>Brain</th>
<th>DDT-MF</th>
<th>PC-12</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENX</td>
<td>0.45 ± 0.02 (5)</td>
<td>0.22 ± 0.03 (5)</td>
<td>11,666 ± 266 (4)</td>
</tr>
<tr>
<td>CXPX</td>
<td>4.4 ± 0.8 (4)</td>
<td>0.13 ± 0.01 (4)</td>
<td>320 ± 40 (5)</td>
</tr>
<tr>
<td>NAX</td>
<td>3.8 ± 0.21 (4)</td>
<td>0.18 ± 0.05 (3)</td>
<td>—</td>
</tr>
<tr>
<td>CPT</td>
<td>4.10 ± 1.30 (4)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

A<sub>1</sub> receptor binding was carried out with [3H]CPX in guinea pig forebrain and cardiac membranes, and in intact DDT-MF cells. A<sub>2</sub> receptor binding was carried out with [3H]NECA in PC-12 cell membranes. Values are mean ± S.E.M. of triplicate determinations in each of four preparations. K<sub>i</sub> values were calculated as described in methods. Abbreviations for the alkylxanthines are as follows: ENX = 1,3-dipropyl-8-[3-oxatricyclo[3.1.0.0<sup>2,4</sup>]oct-6(7)-yl]xanthine; CXPX = 8-cyclopentyl-1,3-dipropylxanthine; NAX = 1,3-dipropyl-4-[3-oxatricyclo[3.1.0.0<sup>2,4</sup>]oct-6(7)]xanthine; and CPT = 8-cyclopentyl-1,3-dinitethylxanthine.

Additional radioligand binding studies have been carried out in guinea pig forebrain (A<sub>1</sub> receptor) and striatum (A<sub>2</sub> receptor) to demonstrate the greater A<sub>1</sub> receptor selectivity of ENX as compared to the previously known adenosine receptor antagonists, NAX or CXPX. Table 4 shows A<sub>1</sub> and A<sub>2</sub> receptor binding affinities of brain tissue expressing A<sub>1</sub> (forebrain) and A<sub>2</sub> (striatum) adenosine receptors. The results of Table 4 clearly illustrate that ENX is significantly more selective for A<sub>1</sub> than A<sub>2</sub> receptors than the other alkylxanthines, NAX and CXPX. That is, ENX was 800-fold selective for A<sub>1</sub> vs. A<sub>2</sub>, whereas NAX and CXPX were only 20 and 7.5 fold selective for A<sub>1</sub> vs. A<sub>2</sub>, respectively. These results of these radioligand binding studies are fully consistent with that of the functional studies in guinea pig isolated hearts.

TABLE 4

<table>
<thead>
<tr>
<th>Alkylxanthine</th>
<th>A&lt;sub&gt;1&lt;/sub&gt; (forebrain)</th>
<th>A&lt;sub&gt;2&lt;/sub&gt; (striatum)</th>
<th>Ratio A&lt;sub&gt;1&lt;/sub&gt;/A&lt;sub&gt;2&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENX</td>
<td>0.45 ± 0.13</td>
<td>360 ± 36</td>
<td>800</td>
</tr>
<tr>
<td>NAX</td>
<td>1.10 ± 0.15</td>
<td>22 ± 6.0</td>
<td>20</td>
</tr>
<tr>
<td>CXPX</td>
<td>8.4 ± 3.00</td>
<td>63 ± 5.40</td>
<td>7.5</td>
</tr>
</tbody>
</table>

A<sub>1</sub> and A<sub>2</sub> receptor binding was carried out with [3H]CPX and [3H]COS in guinea pig forebrain and striatum, respectively. Values are mean ± S.E.M. of triplicate determinations in each of four preparations.

EXAMPLE 4

Activities of ENX Enantiomers

The S-enantiomer and R-enantiomer of ENX were synthesized, as described, and tested for their relative activities and potencies. As shown in Table 5, below, the lower dissociation constant of the S-enantiomer of ENX suggests slightly higher potency (K<sub>i</sub>=0.98) as compared to the R-enantiomer (K<sub>i</sub>=2.1).
substituted amine, e.g., a bicyclic amine, with 6-chloropurine riboside. This straightforward reaction has been commonly used for the synthesis of N⁶-substituted adenosines. See WO 84 04 882 (1985).


An alternative method of generating epoxides is the osmium-catalyzed dihydroxylation of olefins, which is now well known in view of the discovery of phthalazine ligands and that osmate ester hydrolysis is acceleration by sulfur-fumamides. A simple, one-pot procedure for the conversion of vicinal diols into epoxides is known in the art (Kolb, H. C., B. K. Sharpless, supra). This reaction proceeds without epimerization via halohydrin ester intermediates. Combination of these methods allows epoxides to be obtained from olefins in a stereospecific fashion.

The substituted amines which can be used for synthesis of the subject compounds as Structure IV are 3-cyclopenten-1-yl amine (for the cyclopentene oxide derivative of adenosine) or 5-norbornene-2-yl amine (for the cyclohexene epoxide derivative of adenosine). 3-Cyclopenten-1-yl amine can be synthesized from cis-1,4-dichlorobutadiene and dibutyl malonate via a 5-step reaction sequence which is known in the art (Murdock, K. C., R. B. Angier (1962) J. Org. Chem. 27:2395–2398).

The synthesis of 3-norbornene-2-yl amine proceeds from 5-norbornene-2-carboxylic acid, commercially available as a mixture of four isomers, 2R and 2S, each endo and exo. Conversion of this carboxylic acid to acyl chloride, followed by treatment with sodium azide, yields an azide. Curtius rearrangement (loss of N₂ and migration of the substituent group) and subsequent hydrolysis yields 5-norbornene-2-yl amine as a mixture of isomers. This reaction sequence can be performed as a continuous operation without the isolation of the azido or azide in the synthesis of 4-aminocyclohexene. Another variation used for the Curtius rearrangement involves the preparation of the azide by treatment of the corresponding acyl hydrazine with nitrous acid. In both cases, the rearrangement retains the absolute configuration at the chiral center. The endo and exo components can be separated by HPLC methods known in the art.

The synthesis of the optically pure 5-norbornene-2-yl amines involves the use of asymmetric Diels-Alder reactions to obtain intermediate carboxylic acids, followed by a Curtius rearrangement as described above. A general scheme for synthesizing these compounds is shown in FIG. 3.

EXAMPLE 6

Uses, Formulations, and administrations

Therapeutic and prophylactic application of the subject compounds, and compositions comprising them, can be accomplished by any suitable method and technique presently or prospectively known to those skilled in the art.

Further, the compounds of the invention have use as starting materials or intermediates for the preparation of other useful compounds and compositions. The compounds of the invention are useful for various non-therapeutic and therapeutic purposes. It is apparent from the testing that the compounds of the invention have effective antiarrhythmic activity. Specifically, they are useful in regulating cardiac arrhythmia, including PVT, in animals and humans.

The demonstrated effects of both the agonists and the antagonists on cardiac chronotropy, dromotropy, and inotropy make them useful therapeutically as either stimulants or modulators of cardiac performance, thereby affecting function of the heart. For example, the regulation or modulation activity of the subject compounds can affect heart rate (chronotropic effect) and impulse conduction (dromotropic effect). The subject compounds can also be used diagnostically to determine parameters of cardiac function, e.g., as pharmacological reagents useful in determining whether adenosine receptors are mediators of dysfunction of the heart or other organs.

The subject compounds can also serve as standards for in vitro and in vivo studies that measure or compare activities of other agonists and antagonists that act directly or indirectly through adenosine receptors. As reagents for such comparisons, the compounds are valuable pharmacological tools. Their high affinity and selectivity for the A₁ adenosine receptor make them important sources of information about the function of these receptors throughout the body.

Other uses for the subject compounds include their use in the characterization of structure or location of adenosine receptors in organs or tissues. This can be done by, for example, attaching an appropriate label or reporter to the subject compounds by standard techniques or procedures known to persons of ordinary skill in the art. The labels that are suitable for conjugation to the compounds of the subject invention include, but are not limited to, radiolabels (e.g., radioisotopes), fluorescent labels, and biotin labels. Radioisotopes that are suitable for labeling the subject compounds include Bromine-77, Fluorine-18, Iodine-131, Iodine-125, Iodine-125, Iodine-133, Indium-111, Indium-113m, Gallium-67, Gallium-68, Ruthenium-95, Ruthenium-97, Ruthenium-103, Ruthenium-105, Mercury-107, Mercury-203, Rhenium-99m, Rhenium-105, Rhenium-101, Technetium-99m, Tellurium-121m, Tellurium-99m, Tellurium-125m, Thulium-165, Thulium-167, Thulium-168, and Tritium. The gamma-emitting Indium species and Technetium-99m are preferred isotopes because these isotopes are detectable with a gamma-camera and have favorable half lives for imaging in vivo. Alternatively, it would be recognized by those of ordinary skill in the art that non-radioactive labels, for example, enzyme-substrate complexes, e.g., biotin-avidin, horseradish peroxidase-alkaline phosphatase, and the like could be used. Also, fluorescent entities suitable for labeling the subject compounds include fluorescein sodium, fluorescein isothiocyanate, and Texas red sulfonyl chloride. As such, the compounds can be used to visualize, in vitro or in vivo, structure or function of organs or tissues in which the A₁ adenosine receptors are present.

A further embodiment of the subject invention involves the use of the compounds to direct therapeutic compounds to
the A1 adenosine receptor site. Because of the specificity of
the compounds of the subject invention, they can be conju-
gated to therapeutic compounds in order to direct the ther-
peutic compound to the vicinity of the A1 adenosine recep-
tor. Also, in the case of compounds of the subject inventions
which have selectivity to a specific type of tissue, such as
heart tissue, these compounds can be used to direct ther-
aputic or diagnostic reagents to those locations.

The administration of the subject compounds of the
invention is useful as an antiarhythmic agent. Thus, phar-
macological compositions containing compounds of the
invention as active ingredients are useful in prophylactic or
therapeutic treatment of cardiac arrhythmias in humans or
other mammals.

The dosage administered will be dependent upon the
antiarrhythmic response desired; the type of host involved;
its age, health, weight, kind of concurrent treatment, if any;
frequency of treatment; therapeutic ratio and like consid-
erations. Advantageously, dosage levels of the administered
active ingredients can be, for examples, dermal, 1 to about
500 mg/kg; orally, 0.01 to 200 mg/kg; intranasal 0.01 to
about 100 mg/kg; and aerosol 0.01 to about 50 mg/kg of
animal body weight.

Expressed in terms of concentration, the active ingredient
of the invention can be present in the new compositions for
use dermally, topically, intranasally, bronchially, intramuscularly, intravaginally, intravenously, or orally in a
concentration of from about 0.01 to about 50% w/w of the
composition, and especially from about 0.1 to about 30%
w/w of the composition. Preferably, the novel compound is
present in a composition from about 1 to about 10%, and
most preferably, the novel composition comprises about 5%
novel compound.

The compositions of the invention are advantageously
used in a variety of forms, e.g., tablets, ointments, capsules,
pills, powders, aerosols, granules, and oral solutions or
suspensions and the like containing the indicated suitable
quantities of the active ingredient. Such compositions are
referred to herein and in the accompanying claims gener-
ally as “pharmaceutical compositions.” Typically, they can be
in unit dosage form, namely, in physically discrete units
suitable as unitary dosages for human or animal subjects,
each unit containing a predetermined quantity of active
ingredient calculated to produce the desired therapeutic or
prophylactic effect in association with one or more phar-
macrologically acceptable other ingredients, e.g., diluent or
carrier.

Where the pharmaceutical compositions are aerosols, the
active ingredients can be packaged in pressurized aerosol
containers with a propellant, e.g., carbon dioxide, nitrogen,
propane, etc. with the usual adjuvants such as cosolvents,
wetting agents, etc.

Where the pharmaceutical compositions are ointments,
the active ingredient can be mixed with a diluent vehicle
such as cocoa butter, viscous polyethylene glycols, hydro-
genated oils, and such mixtures can be emulsified if desired.

In accordance with the invention, pharmaceutical com-
positions comprise, as an active ingredient, an effective
amount of one or more non-toxic, pharmaceutically accept-
able ingredient(s). Examples of such ingredients for use in
the compositions include ethanol, dimethyl sulfoxide,
glycerol, alumina, starch, calcium carbonate, t alc, flour, and
equivalent non-toxic carriers and diluents.

It should be understood that the examples and embodi-
ments described herein are for illustrative purposes only and
that various modifications or changes in light thereof will be
suggested to persons skilled in the art and are to be included
within the spirit and purview of this application and the
scope of the appended claims.

We claim:

1. A method for protecting renal tissue from damage by a
nephrotoxic agent, said method comprising administering to
a patient an effective amount of a compound having a
structure selected from the group consisting of

wherein R1 and R2 are the same or different, and can be H
or an alkyl group of 1-4 carbons, and n=0-4; and

wherein R1 and R2 are the same or different, and can be H
or an alkyl group of 1-4 carbons, R3 is either O or (CH2)2-4,
and n=0-4.

2. The method, according to claim 1, wherein said com-
 pound has the structure:

wherein R1 and R2 are the same or different, and can be H
or an alkyl group of 1-4 carbons, and n=0-4.

3. The method, according to claim 1, wherein said compo-
und has the structure:

wherein R1 and R2 are the same or different, and can be H
or an alkyl group of 1-4 carbons, and n=0-4.
4. The method for protecting renal tissue, according to claim 3, wherein said compound is an S-enantiomer having the structure:

5. The method, according to claim 3, wherein said compounds is an R-enantiomer having the structure:

6. The method, according to claim 1, wherein said nephrotoxic agent is selected from the group consisting of contrast agents and antibiotics.

7. The method, according to claim 1, wherein said compound is administered in a pharmaceutically acceptable carrier.
CERTIFICATE OF CORRECTION

PATENT NO. : 5,668,139
DATED : September 16, 1997
INVENTOR(S) : Belardinelli \textit{et al.}

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 2, lines 53&54: "\{3-oxatricyclo[3.1.2.0^2,8]oct-6(7)-yl\}" should read
{3-oxatricyclo[3.1.2.0^2,4]oct-6(7)-yl}--

Column 6, line 15: "(but not the A\textsubscript{1} receptor)," should read --(but not the A\textsubscript{2} receptor),--

Column 7, line 59: "became the" should read --because the--

Column 8, line 64: "convening an" should read --converting an--

Column 12, line 24: "The mount" should read --The amount--

Column 14, between Table 5 and Table 6: line 11, should read as following:
--In addition, the S-enantiomer of ENX demonstrated higher binding selectivity for the A\textsubscript{1} receptor. See Table 6, below.

Signed and Sealed this
Sixteenth Day of December, 1997

\textit{Attest:
BRUCE LEHMAN
Commissioner of Patents and Trademarks}